DNA Vaccine Approach Demonstrates 100% Protection Against Unmatched Flu Virus Strains Currently in Circulation

Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses in Animal Studies

Inovio Consensus DNA Vaccine Approach Demonstrates 100% Protection Against Unmatched Flu Virus Strains Currently in Circulation

SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.

Full-text:
http://ir.inovio.com/phoenix.zhtml?c=105128&p=irol-newsArticle_print&ID=1313446&highlight=